Efficacy of nitazoxanide against clinical isolates of Mycobacterium tuberculosis

Antimicrobial Agents and Chemotherapy

Volumn 57, Issue 6, 2013, Pages 2834-2837

  Shigyo, Kristina ^a,b   Ocheretina, Oksana ^a   Merveille, Yves Mary ^c   Johnson, Warren D ^a   Pape, Jean William ^a,c   Nathan, Carl F ^b   Fitzgerald, Daniel W ^a  

^a Global Ctr for Resolution Research   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

^c Centers Institute of Infectious Diseases and Reproductive Health   (Haïti)

Author keywords

[No Author keywords available]

Indexed keywords

ALINA; NITAZOXANIDE; UNCLASSIFIED DRUG;

ANTIBIOTIC RESISTANCE; ARTICLE; BACTERICIDAL ACTIVITY; BACTERIUM ISOLATE; CONTROLLED STUDY; DRUG EFFICACY; MINIMUM INHIBITORY CONCENTRATION; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL;

ANTITUBERCULAR AGENTS; DRUG RESISTANCE, BACTERIAL; HUMANS; ISONIAZID; MICROBIAL SENSITIVITY TESTS; MYCOBACTERIUM TUBERCULOSIS; SPUTUM; THIAZOLES; TUBERCULOSIS, PULMONARY;

EID: 84877866499     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.02542-12     Document Type: Article

References (34)

1. Babu GR, Laxminarayan R. 2012. The unsurprising story of MDR-TB resistance in India. Tuberculosis 92:301-306.
2. Marahatta SB. 2010. Multi-drug resistant tuberculosis burden and risk factors: An update. Kathmandu Univ. Med. J. 8:116-125.
3. Dalton T, Cegielski P, Akksilp S, Asencios L, Campos Caoili J, Cho SN, Erokhin VV, Ershova J, Gler MT, Kazennyy BY, Kim HJ, Kliiman K, Kurbatova E, Kvasnovsky C, Leimane V, van der Walt M, Via LE, Volchenkov GV, Yagui MA, Kang H, Global PETTS Investigators. 2012. Prevalence of and risk factors for resistance to second-line drugs in people with multidrug-resistant tuberculosis in eight countries: A prospective cohort study. Lancet 380:1406-1417.
4. Raviglione MC, Smith IM. 2007. XDR tuberculosis-implications for global public health. N. Engl. J. Med. 356:656-659.
5. The Lancet Infectious Diseases. 2011. The worldwide epidemic of multidrug-resistant tuberculosis. Lancet Infect. Dis. 11:333.
6. Zignol M, Hosseini MS, Wright A, Weezenbeek CL, Nunn P, Watt CJ, Williams BG, Dye C. 2006. Global incidence of multidrug-resistant tuberculosis. J. Infect. Dis. 194:479-485.
7. Loewenberg S. 2012. India reports cases of totally drug-resistant tuberculosis. Lancet 379:205.
8. Velayati AA, Masjedi MR, Farnia P, Tabarsi P, Ghanavi J, Ziazarifi AH, Hoffner SE. 2009. Emergence of new forms of totally drug-resistant tuberculosis bacilli: Super extensively drug-resistant tuberculosis or totally drug-resistant strains in Iran. Chest 136:420-425.
9. Nathan C, Gold B, Lin G, Stegman M, de Carvalho LP, Vandal O, Venugopal A, Bryk R. 2008. A philosophy of anti-infectives as a guide in the search for new drugs for tuberculosis. Tuberculosis 88(Suppl 1):S25-S33.
10. Koul A, Arnoult E, Lounis N, Guillemont J, Andries K. 2011. The challenge of new drug discovery for tuberculosis. Nature 469:483-490.
11. Ortiz JJ, Ayoub A, Gargala G, Chegne NL, Favennec L. 2001. Randomized clinical study of nitazoxanide compared to metronidazole in the treatment of symptomatic giardiasis in children from Northern Peru. Aliment. Pharmacol. Ther. 15:1409-1415.
12. Rossignol JF, Ayoub A, Ayers MS. 2001. Treatment of diarrhea caused by Cryptosporidium parvum: A prospective randomized, double-blind, placebo-controlled study of nitazoxanide. J. Infect. Dis. 184:103-106.
13. Aslam S, Musher DM. 2007. Nitazoxanide: Clinical studies of a broadspectrum anti-infective agent. Future Microbiol. 2:583-590.
14. Stachulski AV, Pidathala C, Row EC, Sharma R, Berry NG, Iqbal M, Bentley J, Allman SA, Edwards G, Helm A, Hellier J, Korba BE, Semple JE, Rossignol JF. 2011. Thiazolides as novel antiviral agents. 1. Inhibition of hepatitis B virus replication. J. Med. Chem. 54:4119-4132.
15. Adagu IS, Nolder D, Warhurst DC, Rossignol JF. 2002. In vitro activity of nitazoxanide and related compounds against isolates of Giardia intestinalis, Entamoeba histolytica and Trichomonas vaginalis. J. Antimicrob. Chemother. 49:103-111.
16. Theodos CM, Griffiths JK, D'Onfro J, Fairfield A, Tzipori S. 1998. Efficacy of nitazoxanide against Cryptosporidium parvum in cell culture and in animal models. Antimicrob. Agents Chemother. 42:1959-1965.
17. Darling JM, Fried MW. 2009. Nitazoxanide: Beyond parasites toward a novel agent for hepatitis C. Gastroenterology 136:760-763.
18. Korba BE, Montero AB, Farrar K, Gaye K, Mukerjee S, Ayers MS, Rossignol JF. 2008. Nitazoxanide, tizoxanide and other thiazolides are potent inhibitors of hepatitis B virus and hepatitis C virus replication. Antiviral Res. 77:56-63.
19. Rossignol JF, Elfert A, Keeffe EB. 2010. Treatment of chronic hepatitis C using a 4-week lead-in with nitazoxanide before peginterferon plus nitazoxanide. J. Clin. Gastroenterol. 44:504-509.
20. Rossignol JF, Kabil SM, El-Gohary Y, Elfert A, Keefe EB. 2008. Clinical trial: Randomized, double-blind, placebo-controlled study of nitazoxanide monotherapy for the treatment of patients with chronic hepatitis C genotype 4. Aliment. Pharmacol. Ther. 28:574-580.
21. Stachulski AV, Pidathala C, Row EC, Sharma R, Berry NG, Lawrenson AS, Moores SL, Iqbal M, Bentley J, Allman SA, Edwards G, Helm A, Hellier J, Korba BE, Semple JE, Rossignol JF. 2011. Thiazolides as novel antiviral agents. 2. Inhibition of hepatitis C virus replication. J. Med. Chem. 54:8670-8680.
22. Elazar M, Liu M, McKenna SA, Liu P, Gehrig EA, Puglisi JD, Rossignol JF, Glenn JS. 2009. The anti-hepatitis C agent nitazoxanide induces phosphorylation of eukaryotic initiation factor 2-via protein kinase activated by double-stranded RNA activation. Gastroenterology 137:1827-1835.
23. de Carvalho LP, Lin G, Jiang X, Nathan C. 2009. Nitazoxanide kills replicating and nonreplicating Mycobacterium tuberculosis and evades resistance. J. Med. Chem. 52:5789-5792.
24. Gold B, Pingle M, Brickner SJ, Shah N, Roberts J, Rundell M, Bracken WC, Warrier T, Somersan S, Venugopal A, Darby C, Jiang X, Warren JD, Fernandez J, Ouerfelli O, Nuermberger EL, Cunningham-Bussel A, Rath P, Chidawanyika T, Deng H, Realubit R, Glickman JF, Nathan CF. 2012. A non-steroidal anti-inflammatory drug sensitizes Mycobacterium tuberculosis to endogenous and exogenous antimicrobials. Proc. Natl. Acad. Sci. U. S. A. 109:16004-16011.
25. National Committee for Clinical Laboratory Standards (NCCLS). 2003. Susceptibility testing of Mycobacteria, Nocardiae, and other aerobic Actinomycetes. NCCLS document M24-A. National Committee for Clinical Laboratory Standards, Wayne, PA.
26. Kamerbeek J, Schouls L, Kolk A, van Agterveld M, van Soolingen D, Kuijper S, Bunschoten A, Molhuizen H, Shaw R, Goyal M, van Embden J. 1997. Simultaneous detection and strain differentiation of Mycobacterium tuberculosis for diagnosis and epidemiology. J. Clin. Microbiol. 35: 907-914.
27. Cowan LS, Diem L, Brake MC, Crawford JT. 2004. Transfer of a Mycobacterium tuberculosis genotyping method, spoligotyping, from a reverse line-blot hybridization, membrane-based assay to the Luminex multianalyte profiling system. J. Clin. Microbiol. 42:474-477.
28. Demay C, Liens B, Burguière T, Hill V, Couvin D, Millet J, Mokrousov I, Sola C, Zozio T, Rastogi N. 2012. SITVITWEB-a publicly available international multimarker database for studying Mycobacterium tuberculosis genetic diversity and molecular epidemiology. Infect. Genet. Evol. 12:755-766.
29. Brudey K, Driscoll JR, Rigouts L, Prodinger WM, Gori A, Al-Hajoj SA, Allix C, Aristimuño L, Arora J, Baumanis V, Binder L, Cafrune P, Cataldi A, Cheong S, Diel R, Ellermeier C, Evans JT, Fauville-Dufaux M, Ferdinand S, Garcia de Viedma D, Garzelli C, Gazzola L, Gomes HM, Guttierez MC, Hawkey PM, van Helden PD, Kadival GV, Kreiswirth BN, Kremer K, Kubin M, Kulkarni SP, Liens B, Lillebaek T, Ho ML, Martin C, Martin C, Mokrousov I, Narvskaïa O, Ngeow YF, Naumann L, Niemann S, Parwati I, Rahim Z, Rasolofo-Razanamparany V, Rasolonavalona T, Rossetti ML, Rüsch-Gerdes S, Sajduda A, Samper S, Shemyakin IG, Singh UB, Somoskovi A, Skuce RA, van Soolingen D, Streicher EM, Suffys PN, Tortoli E, Tracevska T, Vincent V, Victor TC, Warren RM, Yap SF, Zaman K, Portaels F, Rastogi N, Sola C. 2006. Mycobacterium tuberculosis complex genetic diversity: Mining the fourth international spoligotyping database (SpolDB4) for classification, population genetics and epidemiology. BMC Microbiol. 6:23.
30. Stockis A, De Bruyn S, Gengler C, Rosillon D. 2002. Nitazoxanide pharmacokinetics and tolerability in man during 7 days dosing with 0.5 g and 1 g b.i.d. Int. J. Clin. Pharmacol. Ther. 40:221-227.
31. de Carvalho LP, Darby CM, Rhee KY, Nathan C. 2011. Nitazoxanide disrupts membrane potential and intrabacterial pH homeostasis of Mycobacterium tuberculosis. ACS Med. Chem. Lett. 2:849-854.
32. Hoffman PS, Sisson G, Croxen MA, Welch K, Harman WD, Cremades N, Morash MG. 2007. Antiparasitic drug nitazoxanide inhibits the pyruvate oxidoreductases of Helicobacter pylori, selected anaerobic bacteria and parasites, and Campylobacter jejuni. Antimicrob. Agents Chemother. 51:868-876.
33. Korba BE, Elazar M, Liu P, Rossignol JF, Glenn JS. 2008. Potential for hepatitis C virus resistance to nitazoxanide or tizoxanide. Antimicrob. Agents Chemother. 52:4069-4071.
34. Lam KK, Zheng X, Forestieri R, Balgi AD, Nodwell M, Vollett S, Anderson HJ, Andersen RJ, Av-Gay Y, Roberge M. 2012. Nitazoxanide stimulates autophagy and inhibits mTORC1 signaling and intracellular proliferation of Mycobacterium tuberculosis. PLoS Pathog. 8:e1002691. doi:10.1371/journal.ppat.1002691.